MCRB Company Profile and Key Details

Q: Who are the executives of MCRB?

Ms. Paula A. Cloghessy SHRM-SCP, SPHRExecutive Vice President & Chief People OfficerDr. Matthew R. Henn Ph.D.Executive Vice President & Chief Scientific OfficerMr. Thomas J. DesRosier Esq., J.D.Chief Legal Officer, Executive Vice President & Sec.Mr. Jeff YorkVice President of HRDr. David S. Ege Ph.D.Executive Vice President & Chief Technology OfficerMr. Carlo Tanzi Ph.D.Investor Relations OfficerMr. Eric D. Shaff M.B.A.Pres, Chief Executive Officer & DirectorMr. David A. Arkowitz M.B.A.Executive Vice President, Chief Financial Officer & Head of Bus. Devel.Ms. Kristin AinsworthSenior Vice President of Corporation CommunicationsMs. Caroline HoldaAssistant Gen. CounselDr. Teresa L. Young Ph.D., R.Ph.Executive Vice President and Chief Commercial & Strategy OfficerDr. Lisa von Moltke M.D.Executive Vice President & Chief Medical Officer

NASDAQ : MCRB

Seres Therapeutics

$6.49

0.16+2.53%

At Close 4:00 PM

63.4

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Seres Therapeutics, Inc. (MCRB) stock surged +2.53%, trading at $6.49 on NASDAQ, up from the previous close of $6.33. The stock opened at $6.56, fluctuating between $6.10 and $6.74 in the recent session.

Stock Snapshot

6.33

Prev. Close

62.85M

Market Cap

6.1

Day Low

-1.25

P/E Ratio

-5.2

EPS (TTM)

-0.97

Cash Flow per Share

6.56

Open

9.68M

Number of Shares

6.74

Day High

73.78%

Free Float in %

-0.35

Book Value

72.57K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jun 10, 2026	6.47	6.74	6.10	6.49	72.61K
Jun 09, 2026	6.47	6.95	6.20	6.33	83.56K
Jun 08, 2026	6.73	6.99	6.01	6.28	88.89K
Jun 05, 2026	7.80	7.80	6.32	6.63	280.87K
Jun 04, 2026	7.00	7.16	6.62	6.85	132.71K
Jun 03, 2026	7.19	7.72	7.08	7.17	49.5K
Jun 01, 2026	7.35	7.64	7.20	7.64	29.97K
May 29, 2026	7.62	7.75	7.32	7.32	41.79K
May 28, 2026	7.69	7.87	7.48	7.58	39.05K
May 27, 2026	7.70	7.80	7.53	7.63	25.62K
May 26, 2026	7.85	8.10	7.41	7.59	44.82K
May 22, 2026	7.97	8.10	7.64	7.92	21.03K
May 21, 2026	7.51	8.09	7.51	8.05	27.89K
May 20, 2026	7.57	7.69	7.44	7.66	20.1K
May 19, 2026	7.69	7.77	7.43	7.44	28.12K
May 18, 2026	7.53	7.89	7.33	7.59	31.33K
May 15, 2026	7.82	7.90	7.50	7.64	16.94K
May 14, 2026	7.70	8.10	7.60	8.03	36.01K
May 13, 2026	8.02	8.02	7.76	7.76	35.42K
May 12, 2026	7.83	8.10	7.70	7.96	24K

Contact Details

Cambridge, MA 02139

United States

https://www.serestherapeutics.com 617 945 9626

About Company

Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-155, a cultivated bacteria microbiome drug, which is Phase Ib clinical trial to reduce incidences of gastrointestinal infections, bloodstream infections, and graft versus host diseases in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation and solid organ transplants. In addition, the company engages in the development of SER-287 and SER-301 that are in Phase Ib to treat ulcerative colitis; SER-401 for patients with metastatic melanoma; and SER-262 to treat Clostridioides difficile infection. It has license and collaboration agreements with Nestec Ltd. and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Stock Peers

ARGX

-21.82-2.47%

argenx SE$862.18 REGN

-14.53-2.36%

Regeneron Pharmaceuticals, Inc.$601.65 UTHR

-9.04-1.63%

United Therapeutics Corporation$544.10 MDGL

-5.57-1.17%

Madrigal Pharmaceuticals, Inc.$471.32 VRTX

-10.06-2.26%

Vertex Pharmaceuticals Incorporated$435.71 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 KRYS

2.66+0.86%

Krystal Biotech, Inc.$312.41 ALNY

-6.47-2.17%

Alnylam Pharmaceuticals, Inc.$291.22 LGND

4.96+2.04%

Ligand Pharmaceuticals Incorporated$248.24 AXSM

0.7+0.28%

Axsome Therapeutics, Inc.$246.34

Company Overview

Seres Therapeutics, Inc. (NASDAQ:MCRB) closed at $6.49 USD, gaining $0.16 (2.53%) from the previous close of $6.33. The stock is currently mid-range between its 52-week high and low $6.01 and $29.98. With a market capitalization of about $62.85 million, Seres Therapeutics, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.11). Key stats such as the average daily volume over the past year has been around 52.89 thousand shares, in line with its 52-week average. Headquartered in Cambridge, MA, Seres Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Richard N. Kender, the company employs approximately 103 people and listed since June 26, 2015. Seres Therapeutics, Inc. is a pioneering microbiome therapeutics firm dedicated to engineering bacterial consortia that modulate host cells and tissues to combat various diseases.

Technical Performance

Short-term trend indicators are bullishly aligned (SMA20 -22.73%, SMA50 -35.66%, SMA200 -39.01%). The stock’s 14-day RSI is 31.25 (weak momentum), while the ATR of 1.12 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -70.38% below its high and over 35.99% above its low. Average 10-day trading volume of 105.44 thousand shares is significantly above the 3-month average of 53.82 thousand, indicating heightened recent market interest.

Valuation Metrics

Seres Therapeutics, Inc. trades at a P/E ratio of -1.31, slightly below the S&P 500 average, with a price-to-sales ratio of 54.12 and a price-to-book ratio of 2.32 suggesting the stock is closer to book value. The P/FCF stands at -1.46, also above market averages.

Dividend & Fair Value

Seres Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$3.54. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Seres Therapeutics, Inc. generated EPS of $0.61 over the past year. Five-year average earnings growth is 5.33%. The latest quarter delivered EPS of -$2.08. The next quarter is forecast at -$2.11. Next year's EPS is expected at -$33.94. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 2 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $22.00 to $22.00. The high target offers 238.98% upside. The low target suggests 238.98% downside. The mean target is $22.00. This offers 238.98% upside. Seres Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended May 05, 2026, missed forecasts by 10.64%. The prior quarter beat by -20.92%. Over the last six quarters, Apple has recorded several small beats. These include 88.24% in March 13, 2025.

Shareholding & Insider Activity

Seres Therapeutics, Inc. has 8.75 million shares outstanding. The public float is 6.46 million shares, elevated short interest at 19.20% of float. This equals 1.03 million shares. The short ratio is 8.13 days. Institutional investors hold 29.07% of the float. Insiders own 11.83%. AFEYAN NOUBAR holds 5.88 million shares, Nutritional Health LTP Fund General Partner LLC has 5.83 million shares and Pomerantz Roger has 213.98 thousand shares. Over the past six months, insider transactions show net selling. They sold 975.00 shares across 8 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Seres Therapeutics generated $126.33M in revenue, or $0.99 per share. Gross margin was 88.04%, operating margin -84.92%, and net profit margin -90.02%. Returns are negative, with ROA at -31.71% and ROE at 253.53%.
On valuation metrics, Seres Therapeutics trades at a P/E of -1.31, P/S of 54.12 and P/B of 2.32. The current ratio is 1.65 and quick ratio is 1.65. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -541.12 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 3.04, supported by a cash flow-to-debt ratio of -0.52.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Seres Therapeutics posted revenue of $126.33M, down slightly from $7.13M in the prior quarter. Gross profit was $111.21M (margin 88.04%). Operating income was - $107.28M (margin -84.9%). Net income was- $113.72M (EPS - $0.89).
The company ended the quarter with $127.97M in cash and short-term investments, a total debt of $213.94M, and net debt of $85.97M. Total assets were $358.60M, with equity of - $44.86M. Financials further reflected weakness, with operating cash flow of - $117.35M, free cash flow of - $125.33M, and capital expenditures of - $7.98M.

Price Forecast & Outlook

Our AI price prediction model suggests that Seres Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -5.86%, with price expected at $6.11 by June 24, 2026, within a range of $5.51 to $6.61 3-Month Outlook: Projected fall of -27.89%, reaching $4.68 by September 08, 2026, with a range of $3.70 to $5.32. 1-Year Outlook: Projected loss of -75.19%, with price at $1.61 by June 10, 2027, within a range of $0.00 to $0.48.

Key Takeaways

Seres Therapeutics, Inc. (NASDAQ:MCRB) shares are flat 1.21% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Seres Therapeutics, Inc. trading at a premium to the broader market with a P/E of -1.31. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $17.73, suggesting 173.19% upside. Our AI forecast model points to short-term weakness (-5.86% over two weeks), a medium-term fall (-27.89% over three months), and a longer-term loss (-75.19% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Seres Therapeutics, Inc. (MCRB) stock price?

Seres Therapeutics, Inc. (NASDAQ: MCRB) stock price is $6.49 in the last trading session. During the trading session, MCRB stock reached the peak price of $6.74 while $6.10 was the lowest point it dropped to. The percentage change in MCRB stock occurred in the recent session was 2.53% while the dollar amount for the price change in MCRB stock was $0.16.

MCRB's industry and sector of operation?

The NASDAQ listed MCRB is part of Biotechnology industry that operates in the broader Healthcare sector. Seres Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of MCRB?

Ms. Paula A. Cloghessy SHRM-SCP, SPHR
Executive Vice President & Chief People Officer
Dr. Matthew R. Henn Ph.D.
Executive Vice President & Chief Scientific Officer
Mr. Thomas J. DesRosier Esq., J.D.
Chief Legal Officer, Executive Vice President & Sec.
Mr. Jeff York
Vice President of HR
Dr. David S. Ege Ph.D.
Executive Vice President & Chief Technology Officer
Mr. Carlo Tanzi Ph.D.
Investor Relations Officer
Mr. Eric D. Shaff M.B.A.
Pres, Chief Executive Officer & Director
Mr. David A. Arkowitz M.B.A.
Executive Vice President, Chief Financial Officer & Head of Bus. Devel.
Ms. Kristin Ainsworth
Senior Vice President of Corporation Communications
Ms. Caroline Holda
Assistant Gen. Counsel
Dr. Teresa L. Young Ph.D., R.Ph.
Executive Vice President and Chief Commercial & Strategy Officer
Dr. Lisa von Moltke M.D.
Executive Vice President & Chief Medical Officer

How MCRB did perform over past 52-week?

MCRB's closing price is 7.99% higher than its 52-week low of $6.01 where as its distance from 52-week high of $29.98 is -78.35%.

How many employees does MCRB have?

Number of MCRB employees currently stands at 103.

Link for MCRB official website?

Official Website of MCRB is: https://www.serestherapeutics.com

How do I contact MCRB?

MCRB could be contacted at phone 617 945 9626 and can also be accessed through its website. MCRB operates from 200 Sidney Street, Cambridge, MA 02139, United States.

How many shares of MCRB are traded daily?

MCRB stock volume for the day was 72.57K shares. The average number of MCRB shares traded daily for last 3 months was 52.89K.

What is the market cap of MCRB currently?

The market value of MCRB currently stands at $62.85M with its latest stock price at $6.49 and 9.68M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	103
Beta	0.29
Sales or Revenue	$126.33M
5Y Sales Change%	0.422%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

MCRB Company Profile and Key Details

Seres Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Earnings & Analyst Outlook

Shareholding & Insider Activity

Dividend & Fair Value

Technical Performance

Financial & Profitability Overview

Quarterly Financial Highlights

Company Overview

Valuation Metrics

Key Takeaways

Price Forecast & Outlook